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Abstract
Background: The processes that drive fibrotic diseases are complex and include an influx of peripheral blood monocytes
that can differentiate into fibroblast-like cells called fibrocytes. Monocytes can also differentiate into other cell types, such as
tissue macrophages. The ability to discriminate between monocytes, macrophages, fibrocytes, and fibroblasts in fibrotic
lesions could be beneficial in identifying therapies that target either stromal fibroblasts or fibrocytes.
Methodology/Principal Findings: We have identified markers that discriminate between human peripheral blood
monocytes, tissue macrophages, fibrocytes, and fibroblasts. Amongst these four cell types, only peripheral blood
monocytes express the combination of CD45RO, CD93, and S100A8/A9; only macrophages express the combination of
CD45RO, 25F9, S100A8/A9, and PM-2K; only fibrocytes express the combination of CD45RO, 25F9, and S100A8/A9, but not
PM-2K; and only fibroblasts express the combination of CD90, cellular fibronectin, hyaluronan, and TE-7. These markers are
effective both in vitro and in sections from human lung. We found that markers such as CD34, CD68, and collagen do not
effectively discriminate between the four cell types. In addition, IL-4, IL-12, IL-13, IFN-c, and SAP differentially regulate the
expression of CD32, CD163, CD172a, and CD206 on both macrophages and fibrocytes. Finally, CD49c (a3 integrin)
expression identifies a subset of fibrocytes, and this subset increases with time in culture.
Conclusions/Significance: These results suggest that discrimination of monocytes, macrophages, fibrocytes, and fibroblasts
in fibrotic lesions is possible, and this may allow for an assessment of fibrocytes in fibrotic diseases.
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Introduction
There are multiple sources of fibroblast-like cells present in
fibrotic lesions and healing wounds [1–5]. In addition to the
proliferation of resident fibroblasts, bone marrow-derived hema-
topoietic precursors present within the blood are attracted to sites
of injury where they differentiate into spindle-shaped fibroblast-
like cells called fibrocytes, and at least in part, mediate tissue repair
and fibrosis [6–14].
Fibrocytes appear to differentiate from CD14+ peripheral blood
monocytes [7,15–18]. Mature fibrocytes express markers of both
hematopoietic cells (CD34, CD43, CD45, LSP-1, MHC class II)
and stromal cells (collagen I and III) [6–9,16,19]. Fibrocytes also
express the chemokine receptors CCR2, CCR7, and CXCR4,
which regulate their entry into inflammatory lesions [7,16,20–23].
Mature fibrocytes exposed to TGF-b in vitro are able to develop
further into myofibrocytes, a myofibroblast-like population of cells
that express a-SMA and are able to contract collagen gels, in an in
vitro model of wound contraction [7].
At present, there is no single specific marker for fibrocytes. The
combination of intracellular collagen staining and the expression of
CD45 or LSP-1, plus either CD34 or CXCR4, has been considered
as a sufficiently accurate criterion to discriminate fibrocytes from
leukocytes, dendritic cells, endothelial cells and tissue-resident
fibroblasts in vitro and in vivo [8,9]. However, several groups have
shown that the progressive loss of CD34 and eventually CD45 on
fibrocytes can lead to an underestimation of fibrocyte numbers
[8,9,24]. These data suggest that some combinations of markers to
identify fibrocytes do not adequately discriminate different cell
populations, and may lead to either over or underestimation of
fibrocyte numbers [24]. Another problem with the use of CD34,
CD45, CXCR4, LSP-1, and collagen is that even combinations of
these antibodies define overlapping cell types. CD45 and LSP-1 are
expressed by all hematopoietic cells including lymphocytes, mono-
cytes, macrophages, and fibrocytes [16,25,26]. CXCR4 is expressed
by T cells, macrophages, inflammatory fibroblasts, as well as
fibrocytes [27–30]. Besides fibrocytes, CD34 is expressed by
hematopoietic precursors, endothelial cells, stromal cells, and may
be expressed by macrophages and dendritic cells [6,31–33]. The
detection of fibrocytes using intracellular collagen is further
complicated, as fibrocytes only produce low levels of collagen, and
under certain circumstances macrophages may also produce
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Marker
Clone or
Catalog number Isotype Source
CD9 M-L13 Mouse IgG1 BD-Biosciences
CD10 SN5c Mouse IgG1 AbD Serotec, Raleigh, NC
CD11a HI111 Mouse IgG1 BD-Biosciences
CD11b ICRF44 Mouse IgG1 BD-Biosciences
CD11c 3.9 Mouse IgG1 BioLegend
CD13 WM15 Mouse IgG1 BD-Biosciences
CD14 HDC14 Mouse IgG1 BioLegend
CD16 GRM1 Mouse IgG2a Southern Biotechnology
CD18 6.7 Mouse IgG1 BD-Biosciences
CD19 HIB19 Mouse IgG1 eBioscience, San Diego, CA
CD21 FR5A10 Mouse IgG1 Lab Vision, Fremont, CA
CD29 TDM29 Mouse IgG1 Southern Biotechnology
CD31 WM59 Mouse IgG1 BioLegend
CD32 FLI8.26 Mouse IgG2b BD-Biosciences
CD32 AT10 Mouse IgG1 AbD Serotec
CD32a AF1875 Goat polyclonal R&D Systems
CD32b AF1330 Goat polyclonal R&D Systems
CD33 WM53 Mouse IgG1 AbD Serotec
CD34 QBend10 Mouse IgG1 BeckmanCoulter, Miami, FL
CD35 E11 Mouse IgG1 Lab Vision
CD36 SM0 Mouse IgM AbD Serotec
CD41 HIP8 Mouse IgG1 BioLegend
CD43 1G10 Mouse IgG1 BD-Biosciences
CD44 515 Mouse igG1 BD-Biosciences
CD45 HI30 Mouse IgG1 BD-Biosciences
CD45RA HI100 Mouse IgG1 BioLegend
CD45RB MEM-55 Mouse IgG2b BioLegend
CD45RO UCHL1 Mouse IgG2a BD-Biosciences
CD45-B220 RA3-6B2 Rat IgG2a BD-Biosciences
CD49a SR84 Mouse IgG1 BD-Biosciences
CD49b AK7 Mouse IgG1 Millipore
CD49c C3 II.1 Mouse IgG1 BD-Biosciences
CD49d HP2/1 Mouse Igg1 Millipore
CD49e SAM-1 Mouse IgG2b Millipore
CD49f GoH3 Rat IgG2a BD-Biosciences
CD51/61 VI-PL2 Mouse IgG1 BD-Biosciences
CD64 10.1 Mouse IgG1 BD-Biosciences
CD68 Y1/82A Mouse IgG2b BD-Biosciences or BioLegend
CD81 JS-81 Mouse IgG1 BD-Biosciences
CD90 (Thy1) 5E10 Mouse IgG1 BD-Biosciences
CD91 A2MR-a2 Mouse IgG1 BD-Biosciences
CD93 AF2379 Goat polyclonal R&D Systems
CD94 HP-3D9 Mouse IgG1 BD-Biosciences
CD104 450-9D Mouse IgG1 BD-Biosciences
CD105 SN6 Mouse IgG1 AbD Serotec
CD106 STA Mouse IgG1 BioLegend
CD115 3-4A4 Rat IgG2b Santa Cruz Biotechnology, CA
CD117 YB5.B8 Mouse IgG1 BD-Biosciences
CD133 293C3 Mouse IgG2b Miltenyi Biotec Inc., Auburn, CA
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Clone or
Catalog number Isotype Source
CD141 1A4 Mouse IgG1 BD-Biosciences
CD150 A12 (7D4) Mouse IgG1 BioLegend
CD163 GHI/61 Mouse IgG1 BD-Biosciences
CD164 67D2 Mouse IgG1 BioLegend
CD166 3A6 Mouse IgG1 BD-Biosciences
CD169 HSn 7D2 Mouse IgG1 Santa Cruz Biotechnology
CD172a SE5A5 Mouse IgG1 BioLegend
CD172b B4B6 Mouse IgG1 BD-Biosciences
CD180 MHR73-11 Mouse IgG1 BioLegend
CD206 15-2 Mouse IgG1 BioLegend
CD209 DCN46 Mouse IgG2b BD-Biosciences
CD248 (Endosialin) N-16 Goat polyclonal Santa Cruz Biotechnology
CD280 E-17 Goat polyclonal Santa Cruz Biotechnology
CD328 (Siglec-7) F023-420 Mouse IgG1 BD-Biosciences
CD329 (Siglec-9) E10-286 Mouse IgG1 BD-Biosciences
CCR2 48607 Mouse IgG2b R&D Systems
CCR7 150503 Mouse IgG2a R&D Systems
CXCR4 44716 Mouse IgG2b R&D Systems
CX3CR1 TP502 Polyclonal rabbit IgG Torrey Pines BioLabs
Cellular Fibronectin Fn-3 Mouse IgG1 Cymbus Biotechnology
Collagen-I COL-1 Mouse IgG1 Sigma-Aldrich
Collagen-I 600-401-103 Polyclonal rabbit IgG Rockland Inc
Collagen-III 600-401-105 Polyclonal rabbit IgG Rockland Inc
Collagen-IV 600-401-106 Polyclonal rabbit IgG Rockland Inc
Pro-Collagen I M-58 Rat IgG1 Millipore, Temecula, CA:
Cytokeratin C-11 Mouse IgG1 Sigma-Aldrich
Desmin DE-U-10 Mouse IgG1 Sigma-Aldrich
Fibroblasts-Reticular ER-TR7 Rat IgG2a Cedarlane, Burlington, NC
Fibroblasts-Thymic TE-7 Mouse IgG1 Millipore
FAP F11-24 Mouse IgG1 Bender Medsystems, Burlingame, CA
Fibronectin F3648 Polyclonal rabbit IgG Sigma-Aldrich
Bio HA-BP 400763-1A Biotinylated protein Associates of Cape Cod, MA
Lamin B C-20 Goat polyclonal Santa Cruz Biotechnology
LSP-1 16 Mouse IgG1 BD-Biosciences
LYVE AF2089 Goat polyclonal R&D Systems
Mac-2/Galectin-3 eBioM3/38 Rat IgG2a eBioscience
Macrophage-PM-2K PM-2K Mouse IgG1 AbD Serotec
Macrophage- S100A8/A9 Mac387 Mouse IgG1 AbD Serotec
Macrophage-25F9 25F9 Mouse IgG1 eBioscience
Myeloid Ag BM-1 Mouse IgG1 BioLegend
Prolyl-4-hydroxylase 3-2B12 Mouse IgG1 Millipore
PU.1 Sc-352 Polyclonal rabbit IgG Santa Cruz Biotechnology
a-SMA 1A4 Mouse IgG2a Sigma-Aldrich
STRO-1 STRO-1 Mouse IgM DSHB/NIH, University of Iowa
Tenascin BC-24 Mouse IgG1 Sigma-Aldrich
Tubulin YL1/2 Rat IgG2a Novus Biologicals, Littleton, CO
Vimentin-mesenchymal LN-6 Mouse IgM Sigma-Aldrich
Vimentin – all cells VIM-13.2 Mouse IgM Sigma-Aldrich
vWF Goat polyclonal Bethyl Labs, Montgomery, TX
Table 1. Cont.
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Macrophages may also ingest collagen, leading to a false positive
identification of collagen production [39]. These data indicate that
other markers are required to separate fibrocytes from macrophages.
Another major difficulty in analyzing the role of fibrocytes in
fibrotic diseases is the inability to identify markers specific for
fibroblasts [40–47]. Fibroblast subsets can be identified from within
the same tissue or from distinct anatomical sites due to the
expression of different adhesion molecules, extracellular matrix,
chemokine, cytokine and HOX proteins [41–43,48]. Fibroblasts
also differentially express molecules, including CD248/endosialin,
ER-TR7, and gp38/podoplanin, during development and inflam-
mation [42,46,49]. Compounding these issues, markers that initially
appeared to be fibroblast-specific such as FSP-1/S100A4 have since
beenreported to be more widelyexpressed [47,50].Finally, markers
originally defined as specific for monocytes and macrophages such
as CD68 and Mac-2/galectin-3, also label fibroblasts [51–54].
In this report, we have screened freshly isolated human
peripheral blood monocytes (10–15 mm cells that express CD14
with a bilobed nucleus), in vitro-cultured macrophages (15–20 mm
Figure 1. Expression of markers on monocytes, macrophages, fibrocytes, and fibroblasts. Combined data on the expression of markers




Catalog number Isotype Source
Peanut agglutinin (PNA) B-1075 Biotinylated lectin Vector Laboratories
Soybean agglutinin (SBA) B-1015 Biotinylated lectin Vector Laboratories
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from peripheral blood monocytes), in vitro cultured fibrocytes
(50–200 mm long spindle-shaped cells with an oval nucleus derived
from peripheral blood monocytes, that express a variety of
hematopoietic markers such as CD34, CD45, LSP-1, as well as
collagen), and in vitro cultured fibroblasts (stellate-shaped cells
derived from connective tissue, that produce many extracellular
matrix proteins and do not express hematopoietic markers) with
commercially available reagents to identify markers that can
accurately discriminate between these populations.
Methods
Cell culture conditions and fibrocyte differentiation assay
Human peripheral blood was collected into heparin vacutainer
tubes (#367874; BD Bioscience, Franklin Lakes, NJ) from healthy
adult volunteers with specific approval of Rice University’s Institutional
Review Board. Written consent was received and all samples were
de-identified before analysis. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll-Paque Plus (GE Healthcare
Biosciences, Piscataway, NJ) as described previously [16–18]. PBMC
were cultured in serum-free medium (SFM), which consistsof FibroLife
basal media (LM-0001, Lifeline Cell Technology, Walkersville, MD),
supplemented with 10 mM HEPES (Sigma-Aldrich, St. Louis, MO),
1x non-essential amino acids (Sigma-Aldrich), 1 mM sodium pyruvate
(Sigma-Aldrich), 2 mM glutamine (Invitrogen, Carlsbad, CA), 100
U/ml penicillin, 100 mg/ml streptomycin (Sigma-Aldrich), and 1x
ITS-3 (Sigma-Aldrich). PBMC were cultured in flat-bottomed 96 well
tissue culture plates or eight well glass microscope slides (177402, Lab-
Tek, Nalge Nunc International, Naperville, IL) in 200 ml or 400 mlp e r
well respectively, at 2.5610
5 cells per ml in a humidified incubator
containing 5% CO2 at 37uC. Immediately following Ficoll separation
PBMC incubated in 8-well glass slides for 1 hour at 37uCw e r eu s e dt o
analyze, by immunohistochemistry, the expression of markers on
monocytes ex vivo. PBMC were also cultured for 7 days in the presence
of 10% fetal calf serum (FCS; PAA Laboratories, New Bedford,
MA)and 10 ng/ml M-CSF (Peprotech, Rocky Hill, NJ), which are
standard conditions for the culture of human macrophages [55–58].
Cytokines (all from Peprotech) were added at 10 ng/ml. SAP (EMD-
Calbiochem, San Diego, CA) was added at 1 mg/ml. Fibrocytes were
defined as adherent spindle-shaped cells with an oval nucleus, as
described previously [16–18].
Normalhumandermalfibroblasts(Lonza,Walkersville,MD)and
MRC-5 fetal fibroblasts (ATCC, Manassas, VA) were cultured in
RPMI-1640 (Sigma-Aldrich) supplemented with 10% FCS, 100
U/ml penicillin, 100 mg/ml streptomycin, and 2 mM glutamine, as
described previously [59,60]. Human umbilical vein endothelial
cells (HUVEC, Lonza) were cultured in EGM-2 medium (Lonza).
Histology and immunohistochemistry
Serial 5 mm thick sections from patients with Chronic
Obstructive Pulmonary Disease (COPD) or Interstitial Lung
Disease (ILD) were obtained from the National Heart Lung and
Blood Institute-sponsored Lung Tissue Research Consortium
(LTRC), with specific approval of Rice University’s Institutional
Review Board. Written consent was received and all samples were
de-identified before analysis. Sections were either standard
formalin fixed paraffin-embedded sections or ‘‘HOPE fixed’’
before paraffin-embedding [61]. Formalin fixed slides were
dewaxed with xylene, then rehydrated through a graded series
of alcohols and distilled water. HOPE-fixed slides were treated
with 60uC isopropanol for 10 minutes, then treated with fresh
60uC isopropanol for a further 15 minutes. Slides were rehydrated
in 70% acetone (v/v in distilled water), and then distilled water.
Human PBMC cultured on eight well glass microscope slides were
air dried for at least 60 minutes before fixation in acetone for 15
minutes at room temperature.
For all slides, non-specific binding was blocked by incubation in
PBS containing 4% BSA (PBS-BSA) for 60 minutes. Endogenous
biotin was blocked by the addition of streptavidin and biotin
solutions in PBS-BSA, following the manufacturers’ instructions
(Streptavidin/Biotin Blocking Kit, Vector Laboratories, Burlin-
game, CA). Slides were then incubated with 5 mg/ml primary
antibodies in PBS-BSA for 60 minutes (see Table 1 for antibody
list), as described previously [13,16,18,60]. Isotype-matched
irrelevant mouse and rat monoclonal antibodies (BD-Biosciences),
irrelevant rabbit polyclonal antibodies (Jackson ImmunoResearch,
West Grove, PA) or goat polyclonal antibodies (R&D Systems,
Minneapolis, MN), at 5 mg/ml in PBS-BSA were used as controls.
Primary antibodies were detected with either biotinylated goat
F(ab’)2 anti-mouse IgG, biotinylated goat F(ab’)2 anti-rabbit IgG
(both cross-adsorbed against human Ig, Southern Biotechnology,
Birmingham, AL), biotinylated mouse F(ab’)2 anti-rat IgG, or
donkey F(ab’)2 anti-goat IgG (both cross-adsorbed against human
and murine serum proteins, Jackson ImmunoResearch). All
Figure 2. Expression of CD13, CD14, and CD45 isoforms on
fibrocytes. PBMC were cultured in SFM at 5610
5 cells/ml in 8-well
glass slides for 7 days. Cells were then air-dried, fixed, and stained with
antibodies. A) CD13, B) CD14, C) CD45RA, D) CD45RB, E) CD45RO, F)
Irrelevant mouse IgG2a control. Cells were then counterstained with
hematoxylin to identify nuclei. Positive staining was identified by red
staining, with nuclei counterstained blue. Solid arrow points to a
fibrocyte, open arrow points to a macrophage, and asterisk indicates a
cluster of lymphocytes. Photomicrographs are representative results
from at least four different donors. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g002
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minutes. Biotinylated antibodies were detected by a 1/200 dilution
of ExtrAvidin alkaline phosphatase (Sigma-Aldrich or Vector
Laboratories) in PBS-BSA. Staining was developed with the
Vector Red Alkaline Phosphatase Kit (Vector Laboratories) for 7
minutes. Sections were then counterstained for 10 seconds with
Gill’s hematoxylin #3 (Sigma-Aldrich) diluted 1:5 with water,
rinsed in water, and then treated with Scott’s tap water substitute
(20 g/L MgSO4
.7H2O; 2 g/L NaHCO3) for 30 seconds. Slides
were then dehydrated through 70%, 95%, and 100% ethanol,
cleared with xylene, and mounted with VectaMount (Vector
Laboratories). All procedures were performed at room tempera-
ture. Non-specific esterase (a-Naphthyl Acetate) staining was
performed according to the manufacturer’s protocol (a-Naphthyl
Acetate kit, Sigma-Aldrich).
For immunofluorescence staining, following incubation with
primary antibodies as described above, slides were labeled with
biotinylated goat F(ab’)2 anti-mouse IgG (Southern Biotechnol-
ogy), Rhodamine Red-X donkey F(ab’)2 anti-rabbit IgG (Jackson
ImmunoResearch), or NL637 donkey anti-goat IgG (R&D
Systems). After washing, the biotinylated antibodies were
detected with Streptavidin-Alexa 488 (Invitrogen) in PBS-BSA.
Sections were then fixed for 30 minutes in 70% ethanol
containing 0.1% Sudan Black B (Fisher Scientific, Pittsburgh,
PA) to quench tissue autofluorescence [13]. Slides were then
washed in PBS and mounted with VectaShield containing DAPI
(Vector Laboratories).
For staining using both mouse IgG1 and IgG2a monoclonal
antibodies, slides were first incubated with mouse IgG2a antibodies
(UCHL1, CD45RO) and rabbit anti-collagen antibodies. After
Figure3. Expression ofmarkers on fibrocytes, fibroblasts, andendothelial cells. PBMC were cultured as described in Figure 1.Normalhuman
dermal fibroblasts and HUVECs were cultured for 2 days in 8-well glass slides. Cells were then air-dried, fixed, and stained with antibodies against A–C)
CD43, D–F) CD44, G–I) CD45, J–L) LSP-1, and M–O) CD29. Cells were then counterstained with hematoxylin to identify nuclei. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g003
Fibrocyte Markers
PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7475washing, the slides were incubated with Alexa-488 goat anti-mouse
IgG (Invitrogen) and Rhodamine Red-X donkey F(ab’)2 anti-rabbit
IgG. After washing, the slides were incubated for at least 60 minutes
with PBS containing 50% normal mouse serum (Gemini BioPro-
ducts, Woodland, CA) and 2% BSA. After washing, the slides were
then incubated with mouse IgG1 monoclonal antibodies, and then
incubated with isotype-specific biotinylated goat F(ab’)2 anti-mouse
IgG1 (Southern Biotechnology). After washing, the biotinylated
antibodies were detected with Streptavidin-Alexa 647 (Invitrogen).
Sections were then fixed for 30 minutes in 70% ethanol containing
0.1% Sudan Black B, washed in PBS, and mounted with
VectaShield containing DAPI. All procedures were at room
temperature.
Flow cytometry
PBMC were analyzed by flow cytometry as described previously
[18,26,59,60,62,63]. Briefly, human PBMC were incubated with
5 mg/ml primary antibodies diluted in PBS-BSA for 30 minutes on
ice. Isotype-matched irrelevant mouse monoclonal antibodies (BD-
Biosciences) at 5 mg/ml in PBS-BSA were used as controls. PBMC
were then washed twice in ice-cold PBS, before staining on ice for
30 minutes with 2 mg/ml FITC-conjugated goat F(ab’)2 anti-
mouse IgG (cross-adsorbed against human Ig, Southern Biotech-
nology) in PBS-BSA. For 3 color flow cytometry, PBMC were then
incubated in PBS-BSA containing 20% normal mouse serum
(Gemini BioProducts, West Sacramento, CA) for 30 minutes on
ice, to block any remaining anti-mouse IgG binding sites. PBMC
were then washed twice in ice-cold PBS and then stained on ice for
30 minutes with CD16-PE (BD-Biosciences) and CD14-PE/Cy7
(BioLegend, San Diego, CA) in PBS-BSA containing 20% normal
mouse serum. PBMC were analyzed by flow cytometry using an
Accuri C6 cytometer (Accuri, Ann Arbor, MI). Peripheral blood
monocytes were identified by their size, granularity, and
expression of CD14. At least 5,000 CD14 positive monocytes
were examined for each marker.
Image Analysis
Immunohistochemistry images were captured on an Axioskop
microscope (Zeiss, Thornwood, NY) using an AxioCam MRc5
digital camera (Zeiss) and AxioVision software (Zeiss). Immuno-
fluorescence images were captured on an Axioplan2 microscope
(Zeiss) with a CoolSNAP HQ digital camera (Photometrics,
Tucson, AZ) and Metamorph software (Molecular Devices,
Downingtown, PA). Images were analyzed with ImageJ (Rasband,
WS, NIH, Bethesda, MD).
Statistics
Statistical analysis was performed using GraphPad Prism 4
software (GraphPad, San Diego, CA). Differences between
multiple groups were assessed by ANOVA using Tukey’s
post-test. Significance was defined as p,0.05. In the figures,
*** indicates p,0.001.
Results
Expression of markers on fibrocytes cultured for one
week
Fibrocytes, either cultured under a variety of conditions in vitro,o r
isolated from tissues in vivo, have been identified with a variety of
markers, including LSP-1, a-SMA, CD13, CD34, CD45, CCR2,
CXCR4, and collagen-I [6,7,9,11,13,16,20,22]. We confirmed that
human fibrocytes (50–200 mm long spindle-shaped cells with an
oval nucleus), cultured for 7 days in SFM, expressed CD13, CD34,
CD45RB (the intermediate molecular weight isoform of CD45),
CD45RO (the low molecular weight isoform of CD45), CXCR4,
and had undetectable levels of CD14 and CD45RA (the high
molecular weight isoform of CD45) (Figures 1 and 2).
As PBMC cultured in SFM for 7 days contain lymphocytes,
fibrocytes, and in vitro differentiated macrophages, we were able to
compare directly the expression of markers on these cell types in
the same cultures. As reported previously, we found that
lymphocytes (8–10 mm cells, with little or no cytoplasm), ex vivo
monocytes (10–15 mm cells, with a bilobed nucleus), in vitro
cultured macrophages (15–20 mm cells, with a large nucleus and
pronounced cytoplasm), and fibrocytes, all express CD43, CD44,
CD45, LSP-1, CD29 (b1 integrin), and CD18 (b2 integrin)
(Figures 1 and 3) [6,7,9,16,25]. We then performed a screen using
commercially available reagents to determine what markers were
expressed by fibrocytes, compared to freshly isolated PBMC, in
vitro cultured macrophages, fibroblasts, and endothelial cells. The
data are summarized in Figure 1; key observations made with
some of the markers are described below.
Figure 4. Comparison of markers on PBMC ex-vivo and
fibrocytes. PBMC were cultured in SFM at 5610
5 cells/ml in 8-well
glass slides for 1 hour (ex vivo) or 7 days. Cells were then air-dried, fixed,
and stained with antibodies. A and B) CD35, C and D) CD93, E and F)
S100A8/9, G and H) 25F9, and I and J) PM-2K. Cells were then
counterstained with hematoxylin to identify nuclei. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g004
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7475Figure 5. Detection of surface markers on monocytes by flow cytometry. PBMC were stained with mouse monoclonal antibodies and then
analyzed by flow cytometry. Monocytes were identified by their forward and side scatter characteristics and the expression of CD14. Histograms show
fluorescence intensity of isotype control antibody (black line) compared to the indicated marker (red line) on monocytes. Flow cytometry plots are
representative results from six separate donors. Graph shows the percent positive monocytes expressed as the mean6SEM (n=6 separate donors).
doi:10.1371/journal.pone.0007475.g005
Fibrocyte Markers
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fibrocytes
We first assessed the expression of CD11b, CD11c, CD33,
CD35, CD93, calcium binding S100A8/A9 complex (MRP8/14;
calprotectin), 25F9, and PM-2K, markers differentially expressed
by monocytes and macrophages [64–70]. As shown previously, we
found that ex vivo peripheral blood monocytes, incubated for 60
minutes in vitro and identified by their size, expression of CD14,
and a bilobed nucleus, expressed CD33, CD35, CD93, and
S100A8/A9 (Figures 1 and 4). Macrophages and fibrocytes
cultured for 7 days, had low or undetectable expression of
CD33, CD35, and CD93, but retained expression of S100A8/A9
(Figures 1 and 4). The 25F9 antigen, which is absent on monocytes
but expressed by macrophages, was also present on fibrocytes
(Figure 4). PM-2K, a marker expressed only by mature
macrophages, was absent on fibrocytes (Figure 4; and see below).
The relative surface expression of CD11b, CD11c, CD33, CD35,
and 25F9 on peripheral blood monocytes ex vivo was confirmed by
flow cytometry (Figure 5 and data not shown). Both in vitro
cultured macrophages and fibrocytes expressed the sialomucins
CD68 and CD164, the C-type lectins CD206, CD209, and the
scavenger receptor CD163 (Figures 6 and 7). The surface
expression of CD163, CD169, CD206, and CD209 was either
absent or low on peripheral blood monocytes, as determined by
flow cytometry (Figure 5 and data not shown). Macrophages
express non-specific esterase (NSE) staining [71]. Both macro-
phages and fibrocytes were NSE positive, but in macrophages
NSE activity was fluoride insensitive whereas in fibrocytes the NSE
activity was fluoride sensitive (data not shown). We also cultured
PBMC for 7 days in the presence of 10% FCS and 10 ng/ml M-
CSF, which are standard conditions for the culture of human
macrophages [55–58]. We found that macrophages cultured in
10% fetal calf serum and 10 ng/ml M-CSF expressed CD11b,
CD11c, CD13, CD14, CD32, CD68, CD163, CD164, CD169,
S100A8/A9, 25F9, and PM-2K, but CD33 and CD35 were
undetectable (Figure 8 and data not shown). There was no
discernable difference in the expression of CD13, CD68, CD163,
S100A8/A9, and 25F9, between macrophages cultured in SFM
compared to FCS and M-CSF (Figures 2, 4, 6 and 8). However,
we did observe that CD14 and PM-2K were expressed on
macrophages cultured in the presence of serum and M-CSF.
These results suggest that CD33, CD35, CD93, and 25F9
expression can be used to distinguish monocytes from macro-
phages and fibrocytes, and that fluoride-sensitive NSE activity and
PM-2K antigen expression may discriminate fibrocytes from tissue
macrophages.
Expression of FccR receptors
We previously found that the inhibition of fibrocyte differen-
tiation by SAP may act through FccR ligation [17,72]. Therefore,
we examined the expression of FccR on fibrocytes and
macrophages, compared to ex-vivo peripheral blood monocytes.
As described previously, monocytes express CD64 (FccRI) and
CD32 (FccRII), with a subpopulation of monocytes also positive
for CD16 (FccRIII) (Figure 9) [70,73]. The expression of CD16,
CD32, and CD64 on peripheral blood monocytes was confirmed
by flow cytometry (Figure 5). We found that after 7 days in SFM
culture, macrophages expressed CD16 (FccRIII) and CD32
(FccRII), but CD64 (FccRI) expression was undetectable
(Figure 9). Macrophages in populations of PBMC cultured in
the presence of FCS and M-CSF expressed predominantly CD32
(Figure 8). Fibrocytes expressed both CD32a and CD32b isoforms,
but CD16 expression was low and CD64 expression was
undetectable (Figure 9). Both fibroblasts and endothelial cells
had no detectable FccR expression (Figure 1 and data not shown).
Expression of stem cell markers
Compared to peripheral blood monocytes, fibrocytes express
CD34 (Figures 1 and 5) [6,16–18,74]. CD34 is not only a classical
stem cell marker, but a member of the sialomucin family of
receptors, that also includes CD43, CD68, and CD164, which
fibrocytes also express (Figures 3, 6, and 7) [33,75]. CD133,
CD150, and STRO-1 are also markers associated with hemato-
poietic and mesenchymal stem cells, but these markers did not
appear to be expressed by fibrocytes (Figure 1 and data not
shown). The high molecular weight isoform of CD45, CD45-
Figure 6. Expression of monocyte/macrophage markers on fibrocytes. PBMC were cultured as described in Figure 1. Cells were then air-
dried, fixed, and stained with antibodies against A) CD18, B) CD68, C) CD163, D) CD206, E) CD209, and F) mouse IgG1 control. Cells were then
counterstained with hematoxylin to identify nuclei. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g006
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and has been reported to be a marker of certain stem cell
populations [76]. We did not detect the expression of CD45-B220
on monocytes, macrophages, or fibrocytes (Figure 1).
Expression of stromal cell markers
We then examined markers associated with stromal cells.
Fibroblasts and endothelial cells had no detectable staining for
CD43, CD45, and LSP-1, although fibroblasts stained for CD29,
and CD44, and endothelial cells were CD29, CD93 and vWF
positive (Figures 1 and 3, and data not shown). Unlike MRC-5
fetal fibroblasts and normal human dermal fibroblasts (NHDF),
fibrocytes and macrophages had no detectable staining for CD90,
CD248 (endosialin), FAP, TE-7, cellular fibronectin, or hyalur-
onan (HA-BP) (Figures 1, 7, and 8). We were also able to confirm
that normal human dermal fibroblasts and human fetal fibroblasts
(MRC-5) also express CD68 (originally described as a monocyte/
macrophage marker) and CD164 (Figures 1 and 7), as described
previously [51–54]. Fibroblasts also expressed tenascin, and
endothelial cells expressed cytokeratin, but these markers were
undetectable on fibrocytes (Figure 1 and data not shown). These
data indicate that there are at least six commercial reagents
(cellular fibronectin, CD90, TE-7, CD248, HA-BP, and FAP) that
can be used to discriminate between fibrocytes and fibroblasts.
Expression of collagen matrix markers
Fibrocytes showed positive staining for collagen-I, collagen-IV,
pro-collagen-I, and prolyl-4-hydroxylase (a key enzyme in collagen
Figure 7. Comparison of fibroblast markers on fibrocytes, fibroblasts, and HUVECs. PBMC were cultured as described in Figure 1. Normal
human dermal fibroblasts (NHDFb) and HUVECs were cultured for 2 days in 8-well glass slides. Cells were then air-dried, fixed, and stained A–C) for
CD90, D–F) for TE-7, G–I) for CD164, J–L) with HA-BP, and M–O) for cellular fibronectin. Cells were then counterstained with hematoxylin to identify
nuclei. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g007
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found on fibroblasts (Figure 1 and 10). We also detected weak
collagen staining on macrophages cultured in either SFM or with
serum and M-CSF, compared to cells incubated with irrelevant
IgG (Figures 8 and 10). These data suggest that either the
macrophages were able to produce low levels of collagen, or that
the macrophages were able to ingest collagen from other sources
in the culture. The source of collagen is unlikely to be from the
serum-free medium, and is more likely to be from either collagen
bound to the cells before blood collection, or collagen-secreting
cells in the cultures. Antibodies against prolyl-4-hydroxylase or
pro-collagen I only label cells actively synthesizing collagen. There
were low levels of staining on macrophages, cultured in either
SFM or with serum and M-CSF, with both prolyl-4-hydroxylase
and collagen-I antibodies (Figures 1, 8 and 10), indicating that
macrophages may produce collagen, as described previously
[34,38]. These data suggest that the use of collagen staining to
discriminate CD45/CXCR4 or CD34/CD45 positive macro-
phages from CD45/CXCR4/collagen positive or CD34/CD45/
collagen positive fibrocytes may be insufficient to discriminate
macrophages from fibrocytes.
Expression of lectin and carbohydrate residues
As the expression of carbohydrate residues on glycoproteins
change as cells differentiate [77], we assessed whether fibrocytes
expressed different carbohydrates compared to monocytes and
macrophages. Monocytes stained with the lectins wheat germ
agglutinin (WGA) and peanut agglutinin (PNA), but not soybean
agglutinin (SBA), whereas macrophages and fibrocytes retained
the expression of WGA, but did not stain with PNA or SBA (data
Figure 8. Expression of markers on macrophages cultured in
serum and M-CSF. PBMC were cultured in SFM at 5610
5 cells/ml in 8-
well glass slides for 7 days in the presence of 10% FCS and 10 ng/ml M-
CSF. Cells were then air-dried, fixed and stained with 5 mg/ml mouse
IgG1 monoclonal antibodies against CD13, CD14, CD32, CD163, CD90,
mouse IgG1, proyly-4-hydroxylase, 25F9, S100A8/A9, PM-2K, TE-7, and
collagen-I. Cells were then counterstained with hematoxylin to identify
nuclei. Inserts indicate staining at higher magnification. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g008 Figure 9. Comparison of Fc receptors on PBMC ex-vivo and
fibrocytes. PBMC were cultured in SFM at 5610
5 cells/ml in 8-well
glass slides for 1 hour (ex vivo) or 7 days. Cells were then air-dried, fixed,
and stained with antibodies against A and B) CD64, C and D) CD32, E
and F) CD16, G and H) CD32a, I and J) CD32b, or K and L) goat IgG
control antibodies. Cells were then counterstained with hematoxylin to
identify nuclei. Asterisks are to the right of macrophages. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g009
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expressed by macrophages [78]. Both macrophages and fibrocytes
expressed Mac2/Galectin 3 (Figure 1 and 11).
Expression of markers on long-term cultured fibrocytes
We next addressed whether markers expressed by fibrocytes
changed when PBMC were cultured in vitro for up to three weeks.
We found that long-term cultured fibrocytes also expressed many
of the markers expressed by fibrocytes cultured for 1 week, such as
CD18, CD43, CD44, CD45RO, CD49e, CD68, CD163, CD164,
CD169, LSP-1, and CXCR4 (Figure 12 and data not shown). We
observed a reduced expression of CD34, as described previously
(Figure 12) [20]. We also observed that after 3 weeks in culture,
compared to macrophages fibrocytes had undetectable expression
of CD14 and PM-2K (Figures 2, 4, 8, 12, and data not shown).
Using a screen of integrin receptor expression, we found that
compared to the expression of CD49e (a5 integrin) on fibrocytes
and macrophages, the number of CD49c (a3 integrin) positive
fibrocytes increased as cells were cultured for up to three weeks
(Figure 11 and 12). These data suggest that PM-2K may be a
useful marker to distinguish fibrocytes from macrophages, and that
CD49c could be a useful marker to distinguish mature fibrocytes
from younger fibrocytes.
Expression of markers on ‘‘early’’ fibrocytes
We next assessed whether we could identify markers that could
discriminate cells that had the potential to differentiate into
fibrocytes. We screened PBMC at time points before fibrocytes
appeared in the cultures. As described previously, compared to ex
vivo monocytes (Figures 4 and 5), monocytes cultured in vitro for
24 hours had low to undetectable levels of CD14 and CD93 (data
not shown) [69,79]. We did detect the expression of 25F9 antigen
on PBMC cultured for 2 days, as described previously (Figure 1)
[67]. We were also unable to detect collagen, a marker of mature
fibrocytes, by early fibrocyte-like cells (data not shown). Finally, we
assessed whether PU.1 and myeloid antigen, two transcription
factors expressed in monocyte precursors [80,81], were expressed
by cells during the early stages of monocyte to fibrocyte
differentiation. In PBMC cultured for up to seven days in serum
free medium, we did not detect PU.1 or myeloid antigen (Figure 1).
The most characteristic changes associated with early fibrocyte
differentiation were nuclear shape change from a kidney bean
shape to a small oval nucleus, and extensive cytoskeletal
rearrangements as assessed by tubulin and lamin B staining
(Figure 11 and data not shown). These data suggest that currently
the earliest detectable changes in monocytes differentiating into
fibrocytes are morphological changes, rather than specific changes
in receptor expression.
Expression of markers on fibrocytes exposed to cytokines
Both in vitro and in vivo activated macrophages express different
markers when exposed to cytokines, immune complexes, or
Figure 10. Comparison of collagen expression on fibrocytes
and fibroblasts. PBMC were cultured as described in Figure 1. Normal
human dermal fibroblasts were cultured for 2 days in 8-well glass slides.
Cells were then air-dried, fixed, and stained with antibodies. A and B)
collagen-I, C and D) collagen IV, E and F) proyly-4-hydroxylase, G and H)
rabbit IgG control antibody. Cells were then counterstained with
hematoxylin to identify nuclei. Asterisks are to the right of macrophag-
es. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g010
Figure 11. Expression of markers on fibrocytes cultured for 21
days. PBMC were cultured in SFM at 5610
5 cells/ml in 8-well glass
slides for 21 days. Cells were then air-dried, fixed, and stained with
antibodies. A) PM-2K, B) CD18, C) CD34, D) CD68, E) CD163, F) CD164, G)
CD169, H) CD49c, and I) CD49e. Cells were then counterstained with
hematoxylin to identify nuclei. Bar is 50 mm. Graph shows the percent
positive CD49c (a3 integrin) expression over 21 days in culture. At least
100 elongated cells with oval nuclei were examined from at least 10
randomly selected fields, and the percentage of elongated cells that
were positively stained by antibodies against the indicated markers is
expressed as the mean6SEM (n=5 separate donors). *** indicates
p,0.001, as determined by ANOVA.
doi:10.1371/journal.pone.0007475.g011
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fibrocytes also differentially expressed markers in the presence or
absence of IL-4, IL-12, IL-13, and IFN-c, molecules known to
promote or inhibit fibrocyte differentiation [18]. PBMC cultured
in SFM containing IL-4 (or IL-13, data not shown) had increased
numbers of fibrocytes, as described previously [18], and these
fibrocytes stained more intensely for CD206 and CD209, and had
reduced expression of CD172a, compared to fibrocytes cultured in
SFM alone (Figure 13). However, for PBMC cultured in SFM
containing IFN-c (or IL-12, data not shown), the few fibrocytes
observed retained CD172a expression, but had variable expression
of CD206 and CD209 (Figure 13). The presence or absence of IL-
4, IL-12, IL-13, or IFN-c had no apparent effect on the expression
of other markers associated with fibrocytes and macrophages, such
as CD13, CD68, CD163, S100A8/A9, or 25F9 (Figure 13, and
data not shown). These data suggest that as previously described
for macrophages, the markers CD172a, CD206, and CD209 can
be used to determine whether fibrocytes have differentiated in an
environment containing pro-fibrotic Th-2-like cytokines (IL-4 or
IL-13) compared to Th-1-like pro-inflammatory cytokines (IL-12
or IFN-c) [84,85].
Expression of markers on fibrocytes exposed to SAP
We have previously shown that SAP inhibits fibrocyte
differentiation in vitro and in vivo, and that this process appears to
be dependent on the FcRc chain, a common membrane-signaling
component of CD64, CD32a, and CD16 [13,16,17,72]. We
therefore assessed whether PBMC differentially expressed markers
cultured in the presence or absence of SAP. We first assessed
whether the presence of SAP affected the loss of CD93 and gain of
25F9 expression on PBMC, two markers that change rapidly when
cultured in vitro (Figure 4 and data not shown). We found that in
the presence or absence of SAP after 2 days, CD93 expression was
undetectable, and that 25F9 expression was detectable in cells
(data not shown). We than assessed whether SAP altered the
expression of markers on PBMC cultured for 7 days. PBMC
cultured in SFM containing SAP had reduced numbers of
fibrocytes, as described previously [16,17]. PBMC cultured in
the presence of SAP had increased expression of CD14, CD32a,
CD32b, CD163, and CD172a on the macrophages, compared to
cells cultured in SFM alone, whereas markers such as CD45,
CD68, CD164, and PM-2K were unaltered (Figure 14 and data
not shown). These data suggest that the markers CD14, CD32,
CD163, and CD172a, might be used to determine whether
macrophages have differentiated in an environment containing
SAP.
Identification of fibrocytes in pathological samples
Finally, we assessed whether the markers we identified as
specific for monocytes, macrophages, fibroblasts, and fibrocytes
using in vitro cultured cells were valid for human pathological
samples. We stained sections of human lung tissue from patients
with chronic obstructive pulmonary disease (COPD) and intersti-
tial lung disease (ILD) with antibodies against collagen-I, CD32,
CD45RO, CD68, CD93, CD164, LSP-1, PM-2K, and TE-7
(Figure 15 and data not shown). Staining lung tissue from COPD
patients with CD45RO and CD68 antibodies showed the presence
of both small CD45RO positive/CD68 negative cells, which
appear to be lymphocytes, and CD45RO/CD68 dual positive
macrophages and fibrocytes (Figure 15A). We also observed
CD45RO negative/CD68 positive fibroblasts (Figure 15A). Using
CD45RO and PM-2K staining we were also able to discriminate
the small number of CD45RO/PM-2K dual positive tissue
macrophages from PM-2K negative CD45RO positive lympho-
cytes and fibrocytes (Figure 15B). Collagen-I expression was
present throughout the lung, with distinct areas containing
CD45RO and collagen-I dual positive cells (Figures 15C). We
also noted that the majority of PM-2K positive cells were localized
in the alveolar spaces (Figure 15D), suggesting that they are
Figure 12. Comparison of markers on PBMC cultured for 1 day
and day 7 fibrocytes. PBMC were cultured in SFM at 5610
5 cells/ml
in 8-well glass slides for 1 or 7 days. Cells were then air-dried, fixed, and
stained with antibodies. A and B) Lamin B, C and D) galectin-3, E and F)
CD49c, and G and H) CD49e. Cells were then counterstained with
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that PM-2K positive cells did not appear to express collagen
(Figure 15D). We also identified fibroblasts as CD45RO negative/
CD164 positive cells, and fibrocytes as CD45RO/CD164 positive
cells (Figure 15E). Sections stained with CD45RO, TE-7 and
collagen showed large areas of TE-7/collagen dual positive
fibroblasts, and the absence of TE-7 staining on CD45RO
positive cells (Figure 15F). Sections stained with CD32 and TE-7
showed a network of TE-7 positive cells (Figure 15G), whereas
CD32 was restricted to alveolar and interstitial macrophages. We
did not detect any cells that were stained for CD32 and TE-7,
suggesting that these two antibodies label distinct cell types, and
that CD32 is an additional marker to discriminate fibrocytes in
fibrotic lesions (Figure 15G). Finally, using DAPI, CD32, PM-2K,
and collagen we were able to use four color fluorescence to
discriminate macrophages (PM-2K/CD32 positive), fibroblasts
(collagen positive but CD32 and PM-2K negative), and fibrocytes
(CD32/collagen dual positive but PM-2K negative) (Figure 15H).
These data suggest that the expression of PM-2K is absent on
fibrocytes, and that CD164 and TE-7 expression can be used to
identify fibroblasts. Finally, fibrocytes can be identified by using a
combination of antibodies to PM-2K, CD32, CD45RO, and
collagen.
Discussion
In this report, we stained human monocytes, macrophages,
fibrocytes, and fibroblasts with a large panel of antibodies to find
markers that can distinguish these cells. We found that we can
exploit the expression of PM-2K on macrophages and the lack of
PM-2K expression on fibrocytes to distinguish fibrocytes from
macrophages in human in vitro cultured cells and human lung
Figure 13. Effect of cytokines on markers expressed by fibrocytes. PBMC were cultured in 8-well glass slides in SFM for 7 days, in the
presence or absence of IL-4, or IFN-c. Cells were then air-dried, fixed, and stained with antibodies. A–C) CD13, D–F) CD163, G–I) CD172a, J–L) CD206,
and M–O) CD209. Cells were counterstained with hematoxylin to identify nuclei. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g013
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fibrocytes from collagen positive fibroblasts using the expression
of cellular fibronectin, HA-BP or TE-7 on fibroblasts but not
fibrocytes. Finally, we found that CD49c (a3 integrin) appears to
be a marker of fibrocytes that appear after an extended period in
culture.
The PM-2K antibody binds to a 150 kD cytoplasmic protein
that appears to be specific for tissue macrophages, but the gene has
yet to be identified [68]. PM-2K has previously been shown to
stain mature tissue macrophages in humans and non-rodent
mammals [68,86,87]. Due to the differential expression of PM-2K
on macrophages and fibrocytes, we would suggest that PM-2K
expression should be used as a criterion to distinguish these two
cell types, along with morphology and fluoride-sensitive esterase
staining.
Several groups have shown that fibrocytes have a progressive
loss of hematopoietic markers as they differentiate from monocytes
[9,20,24]. Although we did not detect a loss of CD45RO on
fibrocytes, we did detect the loss of CD34. However, we observed
that as monocytes differentiate into fibrocytes, there is an
increased expression of Mac-2/galectin 3, and long-term cultured
fibrocytes express CD49c. These markers may by useful to
discriminate fibrocytes (CD34/CD45RO positive but CD49c
negative spindle-shaped cells with an oval nucleus) from late
differentiating fibrocytes (CD45RO/CD49c positive but CD34
negative spindle-shaped cells with an oval nucleus). Alternatively,
the expression of CD49c may identify a population of fibrocytes
that differentiate from monocytes only after an extended period in
culture.
It is difficult to discriminate fibrocytes with low levels of the
hematopoietic markers CD34 and CD45 from mesenchymal
fibroblasts in tissue sections. We observed that, as reported
previously, fibroblasts express CD68, which precludes it as a
marker to discriminate fibroblasts from macrophages and
fibrocytes [51–54]. However, we found that several fibroblast
markers such as FAP, TE-7, cellular fibronectin, or hyaluronan,
are undetectable on fibrocytes. Therefore, we would recommend
the use of one these markers as a criterion to distinguish fibrocytes
from fibroblast.
We have also been able to show that the loss of CD33, CD35,
CD93, and PNA expression on monocytes and the gain of 25F9
expression on macrophages can be used to differentiate these two
cell types. The loss of CD33, CD35, CD93, PNA, and CD14, and
the gain of 25F9, CD34 and CD49c will distinguish monocytes
from fibrocytes. Finally, the expression of CD11a, CD11b,
CD11c, CD18, CD43, CD45, and LSP-1 on monocytes,
macrophages, and fibrocytes, and the expression of CD90,
hyaluronan, and fibronectin on fibroblasts distinguish these two
sets of cells.
For our analysis of fibrocyte markers, we used commercially
available reagents to remove the issue of limited availability of
antibodies from non-commercial sources. This has the added
advantage that differences in the expression patterns or numbers
of cells between laboratories is less likely to be due to variations in
antibody preparation, and more likely to represent variation due
to tissue processing or an actual variation in the biological process.
These studies indicate that the discrimination of monocytes,
macrophages, fibrocytes, and fibroblasts is possible. In particular,
the accurate discrimination of macrophages, fibrocytes, and
fibroblasts will be beneficial in quantifying these cells in fibrotic
lesions to determine if an increased number of one or more of
these cell types is associated with a fibrotic disease.
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Figure 14. Effect of SAP on markers expressed by macrophag-
es. PBMC were cultured in 8-well glass slides in SFM for 7 days, in the
presence or absence of SAP. Cells were then air-dried, fixed, and stained
with antibodies. A–B) CD14, C–D) CD32a, E–F) CD32b, G–H) CD68, I–J)
CD163, and K–L) CD172a. Cells were counterstained with hematoxylin
to identify nuclei. Bar is 50 mm.
doi:10.1371/journal.pone.0007475.g014
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